Moreover, K252a (TrkB/BDNF inhibitor) treatment could ablate the anti-depressive and anti-inflammatory activities of eFT508, suggesting the regulatory role of eIF4E in the synaptic processes via the TrkB/BDNF signaling during depression development. Here, NTRK2 is linked to major depressive disorder.